Forster Eliot, DIR, reported a transaction classified as grant at Protalix BioTherapeutics, Inc. involving 17000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 17000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
No officer title
The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
Does not include (i) options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033, and (ii) options to purchase 15,000 shares of co…
Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.
0 other filings
0 recent txs